Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Dec 13 Options
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(147)
•••
Post by lonc17on Dec 07, 2023 12:34pm
176 Views
Post# 35773266

Dec 13 Options

Dec 13 Options
It would seem that MC is waiting till the last minute to excersise his 175,000 options.

They expire Wednesday, December 13th.

They are in the money so he will exercise them sometime in the next few days.

Big question, how many of his newly minted shares will he keep?

1.  Holds ALL of them - good news, everyone hang on for a while, the CEO has surprised us and he has confidence in his company.

2.  Holds SOME of them, but sells enough to cover costs - VERY BAD NEWS, the CEO has little confidence in his company, investors would be wise to follow MC's signal and sell.

3.  Holds NONE of them - VERY VERY BAD NEWS, the CEO has no confidence in his company and would rather take the money and run, investors would be wise to sell and delete ONC from their watchlists forever.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities